4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 575.00
-15.00 (-2.54%)
Feb 12, 2026, 4:14 PM GMT
4basebio Revenue
4basebio had revenue of 1.17M GBP in the half year ending June 30, 2025, with 393.28% growth. This brings the company's revenue in the last twelve months to 1.78M, up 198.49% year-over-year. In the year 2024, 4basebio had annual revenue of 933.00K with 84.39% growth.
Revenue (ttm)
1.78M
Revenue Growth
+198.49%
P/S Ratio
51.33
Revenue / Employee
16.17K
Employees
110
Market Cap
91.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 933.00K | 427.00K | 84.39% |
| Dec 31, 2023 | 506.00K | 238.00K | 88.81% |
| Dec 31, 2022 | 268.00K | -70.00K | -20.71% |
| Dec 31, 2021 | 338.00K | -124.00K | -26.84% |
| Dec 31, 2020 | 462.00K | -346.00K | -42.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| Arecor Therapeutics | 5.06M |
| Scancell Holdings | 4.71M |
| SkinBioTherapeutics | 4.64M |
| Ondine Biomedical | 1.18M |
| Avacta Group | 113.00K |
| ImmuPharma | -69.96K |